IP Group plc IPO

IP Group PLC (LSE:IPO) CEO Greg Smith spoke with Proactive's Stephen Gunnion about a strong start to 2026, with NAV per share reaching around 117p and cash proceeds topping £85 million year to date. Smith discussed progress in Pfizer’s obesity programmes, including the berobenatide and amylin combination moving into Phase 2b, alongside further positive data from Pfizer’s lead Phase 3 programme. He also highlighted the wider portfolio, with companies raising more than £540 million of third-party capital in the first half across areas including quantum computing, AI, healthtech and cleantech. IP

SANTA CLARA, Calif. & OXFORD, England, July 21, 2026--Mach42 completes £7m funding round, led by IP Group with investment from BGF and Foresight Group

The pension fund manager has raised its takeover proposal, offering cash, Oxford Nanopore exposure and a biotech kicker to win over IP Group shareholders.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.KEY INFORMATION (a)Full name of discloser:Dimensional Fund Advisors Ltd. whose parent is Dimensional Fund Advisors LP, and also on behalf their investment advisory affiliates (“Dimensional”). The Dimensional entities are investment advisors and Dimensional expressly disclaims beneficial ownership of the shares describe

8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Rathbones Group Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation

LONDON, July 09, 2026-- FORM 8.3